

Date: 28/06/2016

FREEDOM OF INFORMATION REQUEST FOI/012846 – Diagnostic testing for cancer

Do you currently offer a companion diagnostic (stratified medicine) testing services for the following cancer indications and therapies? If so I would be grateful if you could please indicate which tests are offered, the charge per patient test (ideally a comment on what the overhead/kit breakdown of the test cost) and the number performed per year January-December (or month if easier – please specify in comments). The brand name of the test used or any information regarding commercial partnerships would also be appreciated to be included in the comments.

Test Types: IHC = Immunohistochemistry, FISH = Fluorescent In-Situ Hybridization, PCR = Polymerase Chain Reaction, Pyro= Pyrosequencing, NGS = Next Generation Sequencing. If the lab performs another test type or the test is linked to another oncological therapy not listed please check “Other” and include it in the comments section

Indication	Marker	Test type	Charge per patient	Number of test per year	How many tests were used for the following	Comments
Breast Cancer	HER2	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other		2014:	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	
				2015:	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	
		<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other		2014:	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	
				2015:	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	
Colorectal Cancer	KRAS	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other		2014:	<input type="checkbox"/> Cetuximab <input type="checkbox"/> Panitumumab	
				2015:	<input type="checkbox"/> Cetuximab <input type="checkbox"/> Panitumumab	

Non-Small Cell Lung Cancer	EGFR	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	2014:	<input type="checkbox"/> Afatinib <input type="checkbox"/> Erlotinib <input type="checkbox"/> Gefitinib <input type="checkbox"/> Osimertinib	
			2015:	<input type="checkbox"/> Afatinib <input type="checkbox"/> Erlotinib <input type="checkbox"/> Gefitinib <input type="checkbox"/> Osimertinib	
	ALK	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	2014:	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other	
			2015:	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other	
		<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	2014:	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other	
			2015:	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other	
Melanoma	BRAF	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> Pyro <input type="checkbox"/> NGS <input type="checkbox"/> Other	2014:	<input type="checkbox"/> Dabrafenib <input type="checkbox"/> Vemurafenib <input type="checkbox"/> Trametinib	
			2015:	<input type="checkbox"/> Dabrafenib <input type="checkbox"/> Vemurafenib <input type="checkbox"/> Trametinib	
			2015:	<input type="checkbox"/> Dabrafenib <input type="checkbox"/> Vemurafenib <input type="checkbox"/> Trametinib	

**RESPONSE:**

The Trust does not provide this testing.